Study of Safety, Tolerance and Pharmacokinetics of Primapur and Gonal-f Upon Single-dose Subcutaneous Administration in Healthy Volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- IVFarma LLC
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Area Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192))
研究概览
简要总结
The purpose of the current phase I study was to establish bioequivalence, safety, and tolerance of single 300 IU subcutaneous dose of follitropin alfa biosimilar (Primapur) in comparison to that of reference follitropin alfa preparation (Gonal-F) in healthy young female volunteers.
详细描述
A Phase I, prospective, randomized, open-label, crossover, 2-period, two treatment, clinical study in healthy female volunteers.
Objectives of the study:
- To evaluate the frequency and severity of adverse events (AE) following a single 300 IU subcutaneous injection of Primapur (IVFarma, LLC, Russia) and Gonal-F (Merck Serono S.p.A., Italy) to healthy volunteers.
- To determine the AUC0-t value of Primapur following a single 300 IU subcutaneous injection to healthy volunteers.
- To determine the T½ value of Primapur following a single 300 IU subcutaneous injection to healthy volunteers.
- To determine the Сmax value of Primapur following a single 300 IU subcutaneous injection to healthy volunteers.
- To determine the Tmax value of Primapur following a single 300 IU subcutaneous injection to healthy volunteers.
- To compare the obtained pharmacokinetic characteristics of Primapur and Gonal-F.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy female volunteers aged 18 to 40 years.
- •Body mass index (BMI) of 18.5 to 30.0 kg/m
- •Subjects who have used oral contraceptives for at least 2 menstrual cycles before study entry.
- •Regular menstruation cycle (24 to 35 days) before initiation of oral contraception.
- •Presence of both ovaries.
- •Subjects who are negative for drugs of abuse and alcohol tests at screening.
- •Subjects who are healthy as validated by pre study medical history, physical examination.
- •Subjects with acceptable clinical laboratory test results.
- •A signed informed consent form that confirms in writing the volunteer's consent to participate in this clinical study and the volunteer's willingness to comply with all physician recommendations and protocol limitations for the time of participation in the clinical study.
- •Ability to comply with the requirements of the protocol.
- •Participants in the study, as well as their sexual partners, are knowledgeable and willing to voluntarily, starting from the week before being included in the study and up to 4 weeks after the last dose of the study drug, and in addition to the contraceptive used, use at least 1 barrier contraceptive method or spermicide.
排除标准
- •Hypersensitivity to follitropin alpha, combined oral contraceptive (ethinylestradiol and drospirenone) or excipients.
- •Allergy, angioedema (hereditary or idiopathic) in history.
- •Previous history of ovarian hyperstimulation syndrome (OHSS).
- •Inability to establish a venous catheter for blood sampling.
- •Presence of polycystic ovaries (PCO) and ovarian cysts.
- •Neoplasia and a history of malignant disease.
- •Deep vein thrombosis, pulmonary embolism.
- •Subjects with impaired thyroid function.
- •Regular usage or administration of any drugs, including non-prescription drugs, vitamins, homeopathic remedies and dietary supplements, less than 2 weeks before the study (with the exception of contraceptive pills).
- •Admission less than 2 months before the start of the study of drugs that have a pronounced effect on hemodynamics, liver function, and medication contained follicle stimulating hormone (FSH), luteinizing hormone (LH), chorionic gonadotropin (hCG), clomiphene, gonadotropin-releasing hormone (GnRH) analogues.
- •Cardiovascular, bronchopulmonary, nervous, endocrine systems, gastrointestinal tract, liver, kidney, hematopoietic, immune systems, mental diseases.
- •Acute infectious diseases less than 4 weeks before the start of the study.
- •Systolic pressure less than 100 mm or above 130 mm Hg; diastolic pressure less than 70 mm or above 90 mm Hg; heart rate less than 60 or more than 80 beats/min.
- •Blood donation less than 3 months before the start of the study.
- •Participation in clinical studies of drugs less than 3 months before the start of the present study.
- •More than 5 alcohol units per week (1 unit is equal to 50 ml of a strong alcoholic drink, 200 ml of dry wine or 500 ml of beer) or anamnestic information about alcoholism, drug addiction, drug abuse.
- •Smoking more than 5 cigarettes/day.
- •Narcomania, alcoholism.
- •Presence of pregnancy.
- •Any reason that, in the opinion of the investigator, could interfere with safety of the subject or interfere with the objectives of the study.
- •Subjects with a lactose intolerance, lactase deficiency or glucose-galactose malabsorption.
研究组 & 干预措施
Sequence A: Primapur - Gonal-F
Subjects were randomly assigned to receive treatment sequence A: single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Gonal-F.
干预措施: Follitropin alfa (Primapur) (Drug)
Sequence A: Primapur - Gonal-F
Subjects were randomly assigned to receive treatment sequence A: single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Gonal-F.
干预措施: Follitropin alfa (Gonal-F) (Drug)
Sequence B: Gonal-F - Primapur
Subjects were randomly assigned to receive treatment sequence B: single subcutaneous injection of 300 IU Gonal-F on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Primapur.
干预措施: Follitropin alfa (Primapur) (Drug)
Sequence B: Gonal-F - Primapur
Subjects were randomly assigned to receive treatment sequence B: single subcutaneous injection of 300 IU Gonal-F on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Primapur.
干预措施: Follitropin alfa (Gonal-F) (Drug)
结局指标
主要结局
Area Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192))
时间窗: 0-192 hours
Area under curve (AUC), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose. Blood samples to study the pharmacokinetics are to be collected via a venous catheter, which is placed by means of vein puncture before any injection of r-hFSH. Blood sampling were carried out at certain time points according to the specified scheme: - 20 minutes (20 minutes before the drug injection), 0 hours (immediately prior to injection), and 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168, and 192 hours after each injection of the drug product.
Maximum Serum Concentration of Follicle Stimulating Hormone (FSH) (Cmax)
时间窗: 0-192 hours
Maximum serum concentration (Cmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.
次要结局
- Time to Reach a Maximum Follicle Stimulating Hormone (FSH) Serum Concentration (Tmax)(0-192 hours)
- Follicle Stimulating Hormone (FSH) Apparent Terminal Half-life (T1/2)(0-192 hours)